WEREWOLF THERAPEUTICS INC. - COMMON STOCK

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

08 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

22 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

14 ноя 2023 15:25:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

03 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

31 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

27 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

11 сен 2023 15:05:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

05 сен 2023 15:05:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

10 авг 2023 06:10:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

01 июн 2023 06:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

11 май 2023 06:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in May Investor Conferences

01 май 2023 06:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

19 апр 2023 09:00:15 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

23 мар 2023 06:00:00 Источник Nasdaq GlobeNewswire

UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023

16 мар 2023 06:30:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023

15 мар 2023 06:30:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

24 фев 2023 06:30:03 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 фев 2023 06:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting

10 ноя 2022 08:00:02 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

10 ноя 2022 06:00:01 Источник Nasdaq GlobeNewswire